Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo

References

• Bast RJ, Spriggs DR. (2011). More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol 121:429–30.
   PubMed Web of Science ®Google Scholar
• Bouanene H, Miled A. (2010). Conflicting views on the molecular structure of the cancer antigen CA125/MUC16. Dis Markers 28:385–94.
   PubMed Web of Science ®Google Scholar
• Das S, Batra SK. (2015). Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy. Cancer Res 75:4669–74.
   PubMed Web of Science ®Google Scholar
• Doloff JC, Jounaidi Y, Waxman DJ. (2011). Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther 18:153–66.
   PubMed Web of Science ®Google Scholar
• Dwyer RM, Bergert ER, O’Connor MK, et al. (2005). In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 11:1483–9.
   PubMed Web of Science ®Google Scholar
• Felder M, Kapur A, Gonzalez-Bosquet J, et al. (2014). MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer 13:129.
   PubMed Web of Science ®Google Scholar
• Gao P, Zhou GY, Guo LL, et al. (2007). Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter. Cancer Lett 256:81–9.
   PubMed Web of Science ®Google Scholar
• Garg H, Salcedo R, Trinchieri G, Blumenthal R. (2010). Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. Cancer Gene Ther 17:155–63.
   PubMed Web of Science ®Google Scholar
• Higashi M, Yokoyama S, Yamamoto T, et al. (2015). Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Pancreas. 44:728–34.
   PubMed Web of Science ®Google Scholar
• Hong S, Zhang X, Chen J, et al. (2013). Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro. J Ovarian Res 6:80
   PubMed Web of Science ®Google Scholar
• Hong SS, Zhang MX, Zhang M, et al. (2018). Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer. Drug Deliv 25:576–84.
   PubMed Web of Science ®Google Scholar
• Husain SR, Han J, Au P, et al. (2015). Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther 22:554–63.
   PubMed Web of Science ®Google Scholar
• Kaczmarek JC, Kowalski PS, Anderson DG. (2017). Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med 9:60.
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Kim PH, Huyn S, et al. (2010). A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16:6071–82.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Canevari S, Thigpen T. (2015). Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 26:2034–43.
   PubMed Web of Science ®Google Scholar
• Liang C, Qin Y, Zhang B, et al. (2017). Oncogenic KRAS targets MUC16/CA125 in pancreatic ductal adenocarcinoma. Mol Cancer Res 15:201–12.
   PubMed Web of Science ®Google Scholar
• Lo HW, Day CP, Hung MC. (2005). Cancer-specific gene therapy. Adv Genet 54:235–55.
   PubMed Web of Science ®Google Scholar
• Machitani M, Sakurai F, Wakabayashi K, et al. (2017). Enhanced oncolytic activities of the telomerase-specific replication-competent adenovirus expressing short-hairpin RNA against dicer. Mol Cancer Ther 16:251–9.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. (2016). Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154–64.
   PubMed Web of Science ®Google Scholar
• Morgado M, Sutton MN, Simmons M, et al. (2016). Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget 7:14871–84.
   PubMedGoogle Scholar
• Nissim L, Wu MR, Pery E, et al. (2017). Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell 171:1138–50.
   PubMed Web of Science ®Google Scholar
• O’Brien TJ, Beard JB, Underwood LJ, et al. (2001). The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 22:348–66.
   PubMed Web of Science ®Google Scholar
• Perales-Puchalt A, Svoronos N, Rutkowski MR, et al. (2017). Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 23:441–53.
   PubMed Web of Science ®Google Scholar
• Qian Y, Wang Y, Zhang X, et al. (2013). Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. J Proteome Res 12:4046–55.
   PubMed Web of Science ®Google Scholar
• Rama AR, Aguilera A, Melguizo C, et al. (2015). Tissue Specific Promoters in Colorectal Cancer. Dis Markers 2015:390161.
   PubMed Web of Science ®Google Scholar
• Rao TD, Fernandez-Tejada A, Axelrod A, et al. (2017). Antibodies against specific MUC16 glycosylation sites inhibit ovarian cancer growth. Acs Chem Biol 12:2085–96.
   PubMed Web of Science ®Google Scholar
• Sugio K, Sakurai F, Katayama K, et al. (2011). Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res 17:2807–18.
   PubMed Web of Science ®Google Scholar
• Suh DH, Kim M, Kim K, et al. (2017). Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. J Gynecol Oncol 28:e45.
   PubMed Web of Science ®Google Scholar
• Tambe P, Kumar P, Karpe YA, et al. (2017). Triptorelin tethered multifunctional PAMAM-histidine-PEG nanoconstructs enable specific targeting and efficient gene silencing in LHRH overexpressing cancer cells. ACS Appl Mater Interfaces 9:35562–73.
   PubMed Web of Science ®Google Scholar
• Tholey RM, Lal S, Jimbo M, et al. (2015). MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer. Mol Cancer Res 13:439–48.
   PubMed Web of Science ®Google Scholar
• Trujillo MA, Oneal MJ, Davydova J, et al. (2009). Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer. Breast Cancer Res 11:R53.
   PubMed Web of Science ®Google Scholar
• Yamada N, Kitamoto S, Yokoyama S, et al. (2011). Epigenetic regulation of mucin genes in human cancers. Clin Epigenetics 2:85–96.
   PubMed Web of Science ®Google Scholar
• Yang G, Rosen DG, Zhang Z, et al. (2006). The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 103:16472–7.
   PubMed Web of Science ®Google Scholar
• Yin BW, Lloyd KO. (2001). Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371–5.
   PubMed Web of Science ®Google Scholar
• Zhang G, Liu T, Chen YH, et al. (2009). Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res 15:201–7.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen J, Zheng YF, et al. (2009). Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 69:6506–14.
   PubMed Web of Science ®Google Scholar